Nisha Bansal1, Chi-yuan Hsu, Alan S Go. 1. aKidney Research Institute, University of Washington, Seattle, Washington bUniversity of California, San Francisco, San Francisco, California cKaiser Permanente Northern California, Oakland, California, USA.
Abstract
PURPOSE OF REVIEW: Atrial fibrillation is the most common sustained arrhythmia in patients with kidney disease. The purpose of this review is to describe the burden of atrial fibrillation in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), postulate possible mechanisms to explain this burden of disease, understand the clinical consequences of atrial fibrillation and review the treatment options for atrial fibrillation specific to patients with kidney disease. RECENT FINDINGS: Recent literature has revealed that the clinical multiorgan impact of atrial fibrillation in patients with CKD and ESRD is substantial. Although novel oral anticoagulants to treat atrial fibrillation and prevent associated complications have been tested in large trials in the general population, there is a paucity of data on the efficacy and safety of these agents in patients with advanced CKD and ESRD. SUMMARY: Atrial fibrillation is a significant comorbidity in patients with CKD and ESRD with important prognostic implications. More research is needed to understand the mechanisms that contribute to the disproportionate burden of this arrhythmia in patients with kidney disease and in to treatment options specific to this population of high-risk patients.
PURPOSE OF REVIEW: Atrial fibrillation is the most common sustained arrhythmia in patients with kidney disease. The purpose of this review is to describe the burden of atrial fibrillation in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), postulate possible mechanisms to explain this burden of disease, understand the clinical consequences of atrial fibrillation and review the treatment options for atrial fibrillation specific to patients with kidney disease. RECENT FINDINGS: Recent literature has revealed that the clinical multiorgan impact of atrial fibrillation in patients with CKD and ESRD is substantial. Although novel oral anticoagulants to treat atrial fibrillation and prevent associated complications have been tested in large trials in the general population, there is a paucity of data on the efficacy and safety of these agents in patients with advanced CKD and ESRD. SUMMARY:Atrial fibrillation is a significant comorbidity in patients with CKD and ESRD with important prognostic implications. More research is needed to understand the mechanisms that contribute to the disproportionate burden of this arrhythmia in patients with kidney disease and in to treatment options specific to this population of high-risk patients.
Authors: A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev Journal: Am J Kidney Dis Date: 1999-07 Impact factor: 8.860
Authors: Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Irene Capelli; Lorenzo Gasperoni; Marco Ruggeri; Gabriele Donati; Olga Baraldi; Giovanni Sorrenti; Maria Turchese Caletti; Valeria Aiello; Giuseppe Cianciolo; Gaetano La Manna Journal: J Nephrol Date: 2019-04-15 Impact factor: 3.902
Authors: Alexander J Kula; Ronit Katz; Leila R Zelnick; Elsayed Soliman; Alan Go; Michael Shlipak; Rajat Deo; Bonnie Ky; Ian DeBoer; Amanda Anderson; Rob Christenson; Stephen L Seliger; Chris Defilippi; Harold I Feldman; Myles Wolf; John Kusek; Tariq Shafi; Jiang He; Nisha Bansal Journal: Nephrol Dial Transplant Date: 2021-12-02 Impact factor: 5.992